- Home
- NDLS vs MDCX Comparison
NDLS vs MDCX Comparison
Compare NDLS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDLS | MDCX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 16.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | NDLS | MDCX |
|---|---|---|
| Price | $12.36 | $0.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 42.4K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $0.25 |
| 52 Week High | $13.95 | $3.69 |
Technical Indicators
Market Signals| Indicator | NDLS | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 49.97 |
| Support Level | $10.63 | $0.27 |
| Resistance Level | $13.95 | $0.36 |
| Average True Range (ATR) | 1.06 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 51.75 | 54.39 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.